Anti-Aging Compound Polyamines May Also Drive Cancer Growth

The Molecular Switch

The research team identified the specific mechanism that determines which pathway polyamines activate. A small regulatory molecule called miR-6514-5p normally acts as a brake on eIF5A2 production in healthy cells. When polyamines are present at elevated levels — as they would be in someone taking supplements — they disrupt this regulatory molecule, releasing the brake on eIF5A2 in cells that have already undergone cancerous transformation.

This means the same supplement that might be supporting healthy aging in normal tissues could simultaneously be accelerating growth in precancerous or cancerous cells that the individual may not even know they harbor. Given that microscopic cancerous lesions are common in the general population — many never progress to clinical disease — this finding carries significant implications for the millions of people currently taking polyamine supplements.

A Longstanding Puzzle Resolved

The connection between polyamines and cancer is not new. Researchers have known for decades that cancer cells contain abnormally high levels of polyamines and that tumors with the highest polyamine concentrations tend to be the most aggressive. What has been missing is a mechanistic explanation for why molecules that appear beneficial in healthy cells would be associated with malignancy.

The Tokyo University team's work provides that missing link. By identifying the eIF5A1/eIF5A2 switching mechanism and the role of miR-6514-5p in controlling which pathway predominates, the research transforms a correlation into a causal explanation. This is exactly the kind of molecular-level understanding needed to move from observation to actionable medical insight.

Implications for Treatment

Perhaps the most promising aspect of the findings is the identification of eIF5A2 as a potential therapeutic target. If drugs could be developed to selectively block eIF5A2 activation while leaving eIF5A1 function intact, it might be possible to preserve the anti-aging benefits of polyamines while eliminating the cancer-promoting risk.

Such targeted therapies could potentially be used in conjunction with polyamine supplements, or they could serve as standalone cancer treatments for tumors that rely heavily on eIF5A2-driven glycolysis. Either approach would require extensive development and clinical testing, but the identification of a specific molecular target is the essential first step.

What Supplement Users Should Know

The research does not definitively prove that polyamine supplements cause cancer in humans. The molecular mechanisms were identified through laboratory studies, and translating these findings to real-world health outcomes requires clinical data that does not yet exist.

However, the work does provide a scientifically grounded reason for caution. The supplement industry has promoted polyamines — particularly spermidine — based primarily on their positive effects in healthy cell models and animal studies. The Tokyo University research demonstrates that these positive effects represent only half of a more complex biological picture.

For individuals with known cancer risk factors, family histories of certain cancers, or unscreened conditions, the findings suggest that the calculus of polyamine supplementation may be more nuanced than marketing materials indicate. As with many aspects of longevity science, the promise of a simple intervention is complicated by the reality of human biology.

This article is based on reporting by Science Daily. Read the original article.